Physician profile
Linda Yang
NPI 1326482902
$2,373.67
in general payments reported to CMS, 2019-2025
18 companies · $983 in 2025
The $983 reported for 2025 was more than what 77% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $199 · 2020: $35.89 · 2021: $56.78 · 2022: $300 · 2023: $247 · 2024: $553 · 2025: $983.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,682 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,682.44 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $603.47 | 2021-2025 | Clareon, Tryptyr, Rocklatan |
| Amgen INC. | $338.41 | 2024-2025 | Tepezza |
| Horizon Therapeutics Plc | $295.52 | 2021-2023 | Tepezza |
| Mallinckrodt Hospital Products INC. | $229.90 | 2025 | Acthar |
| Harrow Eye, LLC | $194.32 | 2024-2025 | Vevye |
| Astellas Pharma US INC | $143.75 | 2024-2025 | Izervay |
| Ani Pharmaceuticals, INC. | $137.62 | 2024 | Purified Cortrophin Gel |
| Johnson & Johnson Surgical Vision, INC. | $89.42 | 2019-2020 | |
| Oyster Point Pharma, INC. | $55.43 | 2024-2025 | Tyrvaya, Ryzumvi, Ryzumvi |
| Dompe US, INC. | $45.14 | 2024-2025 | Oxervate |
| Bausch & Lomb Americas INC. | $38.41 | 2023-2025 | Xiidra, Scoutpro Osmolarity System |
| Lensar, INC. | $37.82 | 2019 | |
| Abbvie INC. | $35.78 | 2021-2025 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $35.06 | 2019 | |
| Eyevance Pharmaceuticals LLC | $30.37 | 2019 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $23.88 | 2019 | |
| Teleflex LLC | $21.39 | 2023 | Urolift |
| Novartis Pharmaceuticals Corporation | $17.98 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Linda Yang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.